Our first product is a vaccine against SARS-CoV-2, which is based on breakthrough genetic engineering. Leading Swiss expert scientists from immunology, virology, and DNA chemistry have joined forces to translate a novel development concept against the SARS-CoV-2 virus, which has already impacted countless lives worldwide.
Our CEO, Dr. Vladimir Cmiljanovic, talked about the challenges of developing a safe and effective SARS-CoV-2 vaccine in RocketVax for PRVA TV:
Follow our LinkedIn, Instagram, and Facebook page to keep up with our progress.